Jensen, Magnus T.
Sogaard, Peter
Gustafsson, Ida
Bech, Jan
Hansen, Thomas F.
Almdal, Thomas
Theilade, Simone
Biering-Sørensen, Tor
Jørgensen, Peter G.
Galatius, Søren
Andersen, Henrik U.
Rossing, Peter
Funding for this research was provided by:
Hjerteforeningen (12-04-R90-A3840-22725)
European Foundation for the Study of Diabetes (The European Foundation for the Study of Diabetes/)
Article History
Received: 26 February 2019
Accepted: 21 August 2019
First Online: 30 October 2019
Duality of interest
: MTJ has served as consultant on advisory boards or as an invited speaker for Astra Zeneca, Novo Nordisk, Novartis and GE Healthcare. PGJ has received lecture fees from Novo Nordisk. PR has: board memberships for Astra Zeneca, Astellas, Boehringer Ingelheim, Lilly and Novo Nordisk; received grants and/or has grants pending from Novo Nordisk and Astra Zeneca; received payment for lectures (all payments to institution) from Astra Zeneca/BMS, Novartis and Sanofi Aventis; and stocks in Novo Nordisk. HUA is a member of advisory boards for Abbott, Astra Zeneca and Novo Nordisk, has received lecture fees from Nordic Infucare and has stocks in Novo Nordisk. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Free to read: This content has been made available to all.